key: cord-0699858-rk8x974w
authors: Kanitra, John J.; Power, Alexandra D.; Hayward, R. David; Haouilou, Jimmy C.; Edhayan, Elango
title: Malfunctioning Temporary Hemodialysis Catheters in Patients with COVID-19
date: 2020-12-05
journal: J Vasc Surg
DOI: 10.1016/j.jvs.2020.11.033
sha: 854b390776a4bdf47e93ab3f3265c305d7151b2a
doc_id: 699858
cord_uid: rk8x974w

OBJECTIVE: The hypercoagulability seen in COVID-19 patients likely contributes to the high Temporary Hemodialysis Catheter (THDC) malfunction rate. We aim to evaluate prophylactic measures and their association with THDC patency. METHODS: A retrospective chart review of our institutions COVID-19 positive patients who required placement of a THDC between February 1 to April 30, 2020 was performed. The association between heparin locking, increased dosing of venous thromboembolism (VTE) prophylaxis and systemic anticoagulation on THDC patency was assessed. Proportional hazards modeling was used to perform a survival analysis to estimate the likelihood and timing of THDC malfunction with the three different prophylactic measures. We also determined the mortality, rate of THDC malfunction and its association with D-dimer levels. RESULTS: A total of 48 patients with a mortality rate of 71% were identified. THDC malfunction occurred in 31.3% of patients. Thirty-seven patients (77.1%) received heparin locking, 22 (45.8%) received systemic anticoagulation and 38 (79.1%) received VTE prophylaxis. Overall rate of THDC malfunction was lower at a trend level of significance, with heparin vs. saline locking (24.3% vs. 54.6%, p=0.058). The likelihood of THDC malfunction in the heparin locked group is lower than all other groups (Hazards ratio [HR]= 0.07, 95% CI [0.01, 0.45], p=0.005). The rate of malfunction in patients with subcutaneous heparin (SQH) 7,500 units three times daily (TID) is significantly lower than of the rate for patients receiving none (HR=0.03, 95% CI [0.001, 0.74], p=0.032). A trend level significant association was found for SQH 5,000 units vs none (p=0.417) and SQH 7,500 vs 5,000 units (p=0.059). Systemic anticoagulation did not affect THDC malfunction rate (p=0.240). Higher D-dimer levels were related to greater mortality (HR=3.28, 95% CI [1.16, 9.28], p=0.025), but were not significantly associated with THDC malfunction (HR=1.79, 95% CI [0.42, 7.71], p=0.434). CONCLUSIONS: Locking THDC’s with heparin is associated with a lower malfunction rate. Prospective randomized studies will be needed to confirm these findings to recommend locking THDC with heparin in COVID-19 patients. Increased VTE prophylaxis suggested a possible association with improved THDC patency, though the comparison lacked sufficient statistical power.

To date there is a lack of consensus regarding VTE prophylaxis regimens, though there 1 are multiple clinical trials underway, leaving institutions to develop their own protocols. 10, 11 Our 2 institutional guideline, which closely mimics the protocol put forth by Bringham and Women's 3 Hospital, 12 was developed in mid-April 2020. It recommended all COVID-19 patients admitted 4

to the hospital to be on high intensity prophylactic anticoagulation (e.g. SQH 7,500 units three 5 times daily (TID), which a weight > 120 kg qualifier was subsequently added. Systemic 6 anticoagulation was recommended for COVID-19 patients in the intensive care unit (ICU) or for 7 D-dimer levels > 3,000 ngFEU/mL with either the suspicion for thrombosis, lymphocyte count < 8 5%, 13 or increasing D-dimer levels. This D-dimer level is based on retrospective study by Tang 9 et al. demonstrating a significant reduction in mortality with the use of heparin in patients with 10 D-dimer > 6-fold of the upper limit of normal. 14 The rationale for the increased VTE prophylaxis 11 dosing is an upwards of 30% VTE rate seen in COVID-19 patients on standard prophylaxis. 15, 16 12 In ICU patients, a 3-85% VTE rate prompted the systemic anticoagulation recommendation. 11, 17, 13 18 Due to the timing of this protocol becoming available and the disarray caused by the 14 pandemic, there were breaks in adhering to this protocol. 15 For analysis, patients were recorded as receiving a prophylactic measure if they received 16 it at any point during the study period. Because patients received various combinations of the 17 three treatment modalities, it was not possible to identify each individual with a unique treatment 18 arm. Instead, the analytic strategy used was to include three binary variables, each indicating 19 whether or not each treatment was used with each patient (0 = treatment not used, 1 = treatment 20 used). For the THDC malfunction analysis, the prophylactic treatments used for analysis were 21 those received prior to death or the first catheter malfunction. Patients on SQH 5,000 twice daily 22 (BID) and TID were combined for analysis. Increased VTE dosing group received SQH 7,500 1 units TID. The primary outcome is the incidence of THDC malfunction attributed the clotting 12 requiring intervention (manual de-clotting, exchanging catheter over a wire, instillation of 13 alteplase or HD catheter inserted at new location) to re-establish flow. Clotting was diagnosed by 14 visualization of the blood clot during catheter exchange or restoration of flow following manual 15 de-clotting or alteplase. 16

The secondary outcome was the patients' final disposition: renal recovery, requiring 17 dialysis at discharge (permanent dialysis) or mortality. 18 A proportional hazards regression analysis was performed based on the date of THDC 19 insertion and number of days to outcome. Active inpatients and patients who did not experience 20 THDC malfunction were not included in the analysis of catheter malfunction. 21 22

The primary analyses were conducted using proportional hazards modeling (Cox 1 regression) with the outcome variable defined as time from line insertion to catheter malfunction. 2

Using this method, the outcome variable is constructed using two elements: a binary variable 3 indicating whether or not each patient experienced the outcome during the study period, and a 4 time variable representing the time at which the patient either experienced the event or exited the 5 study for another reason (censoring). For each predictor, the proportional hazards model 6 estimates an effect that can be expressed in terms of a hazards ratio (HR). The HR provides an 7 estimate of the relative likelihood that the outcome will occur at any given point in time. 8 Independent variables included as control predictors in the model include patient age, sex, 9 comorbidities (hypertension, high BMI, diabetes, CKD or ESRD, and COPD), pre-hospital anti-10 coagulant therapy, and catheter insertion location (femoral vs. IJ and right vs. left side). 11

Additionally, two sets of sensitivity analyses were conducted to address two potential 12 sources of ambiguity in the interpretation of the results. First, a competing risks analysis was 13 conducted to examine how treating mortality as a competing risk for THDC malfunction may 14 affect the results. Second, a time-varying analysis nesting treatment segments within patients 15 (i.e., unique combination of treatment modalities and/or outcomes) was conducted to better 16 control for differences in treatment timing and duration. 17

Additional analyses were conducted to examine the association between D-dimer levels 18 and outcomes in the subset of patients for whom D-dimer measurements were collected. The 19 relationships between mean maximum D-dimer levels and outcomes were assessed using t-tests. 20 D-dimer levels in the proportional hazard model were transformed by the natural log to enhance 21 the interpretability of the effect size estimates. 22

From February 1 to April 30, 2020, 49 patients with COVID required THDC placement. 2

One patient was eliminated due to mortality prior to the catheter being used, leaving 48 patients 3 for statistical analysis. Forty-six were confirmed COVID-19 positive. Two patients tested 4 negative, however, had a clinical presentation compatible with COVID-19, were managed as 5 false-negatives, and therefore were included in the analysis. Forty-four (92%) were treated in the 6 ICU. Throughout the study period, 37 patients (77.1%) received heparin locking, 22 (45.8%) 7 received systemic anticoagulation and 38 (79.2%) received VTE prophylaxis. Thirty-two 8 (66.7%) patients received more than one prophylactic measure. A total of 24 patients received 9 systemic anticoagulation throughout the study period, however two were started on 10 anticoagulation following the first THDC failure so they were eliminated from the THDC failure and their associations with treatment variables was performed to demonstrate which patient 22 variables may act as confounders (Table I) . Patient variables can be found in Table II . Chi-23 square analysis presented in Table II compare the listed level of the predictor with other levels of 1 the predictor for the corresponding outcome. For example, 24.3% of patients who were receiving 2 heparin locking experienced HD failure, which is significantly lower than patients not receiving 3 heparin locking who also experienced HD failure. Patients were in the study for a median of 7 4 days (range 0 -53 days; IQR 2.5 -14 days) prior to final disposition. 5

Malfunction of the THDC occurred in 15 (31.3%) patients. Median time to THDC 6 malfunction from insertion date was one day (range 0 -17 days, IQR 1 -9 days). Among 7 patients without malfunction, 24 died (median time to death 4.5 days, range 0 -14 days; IQR 1.5 8 -7.5 days), 4 received permanent catheterization (median time 21 days; range 14 -25 days; IQR 9 16 -24.5 days), 4 experienced renal recovery (median time 13 days; range 4 -29 days; IQR 6 -10 23.5 days). All patients were censored at the time of any competing event (death, permanent 11 catheterization, or renal recovery) or at the study end date if they did not experience failure or 12 any competing outcome. Overall rate of THDC malfunction was lower with heparin vs. saline 13 locking (24.3% vs. 54.6%, p=0.058) (Table II) There was no difference in mortality rate between patients who experienced catheter 20 malfunction and those who did not (66.7% vs 72.7%, χ 2 = 0.183, p = 0.669). 21

Thirty-one (64.6%) patients were on VTE prophylaxis at the time of catheter insertion. 22

Of the 17 (35.4%) not on VTE prophylaxis, seven began VTE prophylaxis following line 23 insertion (median 2.5 days, IQR 1 -5 days) and seven were on systemic anticoagulation, leaving 1 three (6.3%) not on systemic or prophylactic anticoagulation during the study period. All three of 2 these patients died within one day of line insertion. A majority of patients on VTE prophylaxis, 3 23 (74.2%) received SQH 5,000 units TID, followed by 7,500 units TID (25.8%), and one 4 patient (3.2%) received 5,000 units BID. Dosing of VTE prophylaxis was increased from 5,000 5 to 7,500 units TID during the study period in seven (22.5%) patients. Of the 15 patients on SQH 6 7,500 units TID, median weight was 119.1 (range 59-214; IQR 86.4 -150.2) kg and all were 7 ICU patients. According to the proportional Hazards model (Table III) , the rate of malfunction at 8 in patients with SQH 7,500 units TID is estimated to be 3% of the rate for patients not receiving 9 VTE prophylaxis (p = 0.032) and in patients receiving SQH 5,000 units TID, 49% of the rate for 10 patients not receiving VTE prophylaxis (p = 0.417). No significant difference was observed 11 between SQH 5,000 TID vs 7,500 TID (p = 0.059). 12

Eighteen patients had D-dimer levels for analysis. There was no difference in D-dimer 13 levels between patients with THDC malfunction and without (11,892 + 5,901 vs. 10,154 + 5,934, 14 p = 0.560). D-dimer was significantly higher in patients who did not survive compared to those 15 that did (12,721 + 5,376 vs. 5,054 + 2,046, p = 0.007). Proportional hazards modeling indicated 16 that higher D-dimer levels were related to greater hazards of mortality (b = 1.19, HR = 3.28, 95% This retrospective cohort study was designed as a result of a high incidence of 4 malfunctioning THDC seen in COVID-19 patients. Our institution was overwhelmed with 5 COVID-19 patients during the study period and patients could not be assigned to definitive study 6 arms. During the study period all modalities were used at physician discretion to prevent THDC 7 malfunction. Locking HD catheters with heparin was independently associated with both a 8 decreased malfunction rate and a longer time to malfunction. 9

Acute kidney injury (AKI) is present in 0.5% 1 -7% 2 of COVID-19 cases and in 23% 3 -10 29% 4 that require intensive care admission. The cause is likely multifactorial: direct viral 11 damage, systemic inflammation, hypoxemia and iatrogenic hypovolemia during the management 12 of acute respiratory distress syndrome (ARDS). 7 The binding affinity of the COVID-19 virus to 13 angiotensin converting enzyme (ACE) 2, which is highly expressed in the brush border of 14 proximal tubular cells, induces AKI and contributes to the dissemination of the virus. [19] [20] [21] [22] [23] As 15 observed in ARDS, cytokine release syndrome may contribute to AKI via interleukin 6 (IL-6). 20, 16 24 17 Previous literature is inconclusive on the best locking solution for central venous 18 catheters. 25 A 2018 Cochrane review concluded that heparin may have little or no effect on 19 catheter patency, but that most studies were of low-quality evidence. 26 Almost one-third (31.3%) 20 of our THDC malfunctioned, highlighting the importance of identifying the most efficacious 21 prophylactic modality. 22

Three prophylactic treatments were utilized at our institution to combat this high 1 malfunction rate: locking the HD catheters with heparin, systemic heparin and increasing the 2 dose of VTE prophylaxis. In the current study, patients whose THDC were locked with heparin 3 had a 92% lower chance of catheter malfunction, resulting in longer time to malfunction and an 4 overall lower likelihood of malfunction. This potential benefit of heparin locking may be 5 reflective of the hypercoagulable patient population. The increased dose of VTE prophylaxis, 6 SQH 7,500 units, also showed some benefit. A significant improvement in THDC patency was 7 seen in patients on SQH 7,500 units TID compared to no VTE prophylaxis, which was not true 8 for SQH 5,000 units TID. A significant association was not seen between SQH 7,500 and 5,000 9 units TID, due to the small sample size. However, this does suggest a possible benefit and the 10 need for further study. Interestingly, systemic anticoagulation had no significant effect on 11 malfunction rate. 12

We found that femoral insertion had significantly greater likelihood of catheter 13 malfunction than IJ insertion in contrary to prior literature. The high malfunction rate is likely a result of the hypercoagulability that has been 5 suggested in COVID-19 patients. Reports describe COVID-19 patients without predisposing 6 factors developing thromboembolic events. 31, 32 The etiology of this is thought to be endothelial 7 damage driven by the cytokine storm, leading to excess thrombin formation in addition to 8 increased blood viscosity from hypoxemia. 9, 32 9

We looked at the relationship between D-dimer levels and malfunctioning THDC to 10 assess the possible utility of using D-dimer levels to predict which patients are more likely to 11 have catheter malfunction. However, we found no difference in D-dimer levels between those 12 with and without THDC malfunction. We did find higher D-dimer levels are associated with 13 higher mortality, which is consistent with prior literature. 9 Only 18/48 patients had D-dimer data. 14 However, most of the patients with D-dimer data were at the end of our study period, likely a 15 reflection of providers catching up with rapidly updating recommendations. 16 HTN and DM are the most common comorbidities associated with COVID-19, which is 17 supported by our study. 33 CKD is seen in 1-3% of COVID patients. 33 The Centers for Disease 18

Control and Prevention (CDC) states risk factors for severe illness from COVID-19 are age > 65, 19 COPD, heart conditions, immunocompromised, BMI > 40, DM, CKD and liver disease. 34 We 20 did not find a difference in mortality rate in patients with these comorbidities (Table II) . 21

However, the high mortality rate of our entire cohort likely obscures the impact of these 22

The incidence of AKI requiring HD in COVID-19 patients is low. However, our study 1 demonstrated a mortality rate of 71% in COVID-19 patients that required a THDC. This is 2 consistent with prior coronaviral infections such as SARS and Middle East respiratory syndrome 3 where a 60-90% mortality rate was seen. 35 This has important implications for planning and 4 resource delegation for future coronaviral infections. 5

The retrospective nature of the current study eliminated the ability to control the 6 independent variables resulting in most patients receiving multiple prophylactic measures at 7 differing time points. This variability is due to the lack of guidelines, hence necessitating the 8 need for this study. We controlled for these multiple measures on a single patient using 9

proportional hazards modeling. Our study reached statistical significance for heparin locking and 10 increased dosing of VTE prophylaxis in reducing rates of THDC malfunction. The observational 11 single institution design can affect its generalizability but it would be difficult to randomize 12 patients in an acute pandemic. Additionally, it was not possible to evaluate interactions between 13 treatment modalities, due to the small numbers of patients who received each potential 14 combination of treatments. Although the power is low (n = 48), this is the largest study to date 15 addressing THDC malfunction in COVID-19 patients. 16

The hypercoagulability in COVID-19 patients increases the malfunction rate of THDC. 18

Heparin locking of THDC was associated with decreased malfunction rates. Prospective 19 randomized studies will be needed to confirm these findings to recommend locking THDC with 20 heparin in COVID-19 patients. Increased VTE prophylaxis suggested a possible association with 21 improved THDC patency, though the comparison lacked sufficient statistical power. 22

Additionally, the current study found an 71% mortality rate in COVID- 19 12.5 †p < .10, * p < .05 NOTES: One patient discharged to hospice and therefore was not included in the outcome data above. Significance values represent results of chi-square test for predictor group by outcome status. Percentages in outcome columns represent the percent of patients in the predictor group with the corresponding outcome. Competing risks regression was implemented using Fine and Gray's method, which is based on modeling the cumulative incidence function. 1 This method differs from ordinary Cox regression in that it is models proportional subdistribution hazards, weighting cases with competing outcomes differently than censored cases, such that the weight of a case with a competing outcome decreases over time as a function of the likelihood that the event of interest would have occurred. 2 Results of the competing risks model are presented in Table A Results are presented in Table A 

Coronavirus Disease 2019 in China

DoD COVID-19 Practice Management Guide

Clinical features of patients infected 5 with 2019 novel coronavirus in Wuhan

Clinical course and outcomes of 7 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, 8 retrospective, observational study

Kidney disease is 10 associated with in-hospital death of patients with COVID-19

Acute renal impairment 12 in coronavirus-associated severe acute respiratory syndrome

High 14 risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective 15 cohort study

Clinical observation and management of COVID-19 patients

Abnormal coagulation parameters are associated with 19 poor prognosis in patients with novel coronavirus pneumonia

COVID-19 and VTE/Anticoagulation: Frequently Asked 14

Anticoagulant treatment is associated with 12 decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

ICU 18 Patients With COVID-19

Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous 2 catheters in adults

Central venous access sites for 4 the prevention of venous thrombosis, stenosis and infection

Intravascular 7 Complications of Central Venous Catheterization by Insertion Site

Central vein 10 stenosis in a dialysis patient: a case report

Central Venous Occlusion in the Hemodialysis Patient

Acute pulmonary embolism and COVID-19 14 pneumonia: a random association?

Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease

Aldosterone System Inhibitors in Patients with Covid-19

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Using the PHREG Procedure to Analyze Competing-Risks Data2014